| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | nelarabine | CTRPv2 | pan-cancer | AAC | 0.004 | 0.9 |
| mRNA | Mdivi-1 | CTRPv2 | pan-cancer | AAC | 0.0037 | 0.9 |
| mRNA | GSK4112 | CTRPv2 | pan-cancer | AAC | -0.0037 | 0.9 |
| mRNA | Vandetanib | CTRPv2 | pan-cancer | AAC | -0.0036 | 0.9 |
| mRNA | ML006 | CTRPv2 | pan-cancer | AAC | -0.0036 | 0.9 |
| mRNA | CAY10594 | CTRPv2 | pan-cancer | AAC | 0.0035 | 0.9 |
| mRNA | Bleomycin | CTRPv2 | pan-cancer | AAC | 0.0035 | 0.9 |
| mRNA | KIN001-244 | GDSC1000 | pan-cancer | AAC | 0.0024 | 0.9 |
| mRNA | vorinostat:navitoclax (4:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0026 | 0.9 |
| mRNA | S-Trityl-L-cysteine | FIMM | pan-cancer | AAC | -0.013 | 0.9 |